Extended-release niacin raises adiponectin and leptin
Sabine Westphal1, Katrin Borucki, Elena Taneva
1Institute of Clinical Chemistry, Magdeburg University Hospital, Leipziger Str. 44, D-39120 Magdeburg, Germany. Sabine.Westphal@Medizin.Uni-Magdeburg.de
Atherosclerosis
|August 5, 2006
Summary
Niacin significantly increases adiponectin levels in men with metabolic syndrome but does not improve insulin sensitivity or endothelial function. This suggests limited atheroprotective benefits despite changes in adipokines.
Area of Science:
- Endocrinology
- Metabolic Syndrome Research
- Cardiovascular Disease Research
Background:
- Niacin, a lipid-lowering drug, is gaining attention for raising HDL-cholesterol and slowing intima-media thickness progression in coronary heart disease patients.
- Niacin's known action on adipocytes prompted an investigation into its effects on adipokines and their associated functions.
Purpose of the Study:
- To investigate the impact of extended-release niacin on adipokines and their related functions in men with metabolic syndrome.
- To assess whether niacin improves insulin sensitivity, anti-inflammatory markers, and endothelial function.
Main Methods:
- A 6-week randomized, placebo-controlled, double-blind study involving 30 men with metabolic syndrome.
- Participants received either 1500 mg of extended-release niacin (n=20) or a placebo (n=10).
- Measurements included adiponectin, leptin, resistin, TNF-alpha, IL-6, high-sensitivity CRP, endothelial function, and HOMA index.
Main Results:
- Extended-release niacin significantly increased adiponectin (56%) and leptin (26.8%) levels.
- Resistin, TNF-alpha, IL-6, and high-sensitivity CRP levels remained unchanged.
- No improvement in endothelial function was observed; the HOMA index (insulin resistance) significantly deteriorated by 42%.
Conclusions:
- Short-term niacin treatment markedly increases adiponectin but does not enhance atheroprotective functions.
- Niacin failed to improve insulin sensitivity, anti-inflammatory effects, or endothelial function in this cohort.
- The study indicates potential limitations of niacin in improving key metabolic and cardiovascular markers despite adipokine modulation.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...